140 filings
DEFA14A
HUMA
Humacyte Inc
29 Apr 24
Additional proxy soliciting materials
7:16am
DEF 14A
HUMA
Humacyte Inc
Definitive proxy
29 Apr 24
7:12am
S-8
HUMA
Humacyte Inc
28 Mar 24
Registration of securities for employees
8:55am
10-K
2023 FY
HUMA
Humacyte Inc
Annual report
28 Mar 24
8:06am
8-K
HUMA
Humacyte Inc
22 Mar 24
Humacyte Fourth Quarter and Year End 2023 Financial Results and Business Update
7:06am
8-K
t6n1br
4 Mar 24
Humacyte, Inc. Announces Proposed Public Offering of Common Stock
6:53am
424B5
7cpnx
1 Mar 24
Prospectus supplement for primary offering
4:05pm
424B5
qnxdmt3 m16wdxd
29 Feb 24
Prospectus supplement for primary offering
4:11pm
8-K
deiqf
29 Feb 24
Other Events
4:02pm
8-K
tj7n0960trgtrrphdz
9 Feb 24
Human Acellular Vessel™ (HAV™) Biologics License Application Granted Priority Review by U.S. FDA for the Treatment of Vascular Trauma
8:06am
8-K
04ggv2bjyhocv na1
12 Dec 23
Other Events
8:06am
8-K
v4khet99
9 Nov 23
Humacyte Third Quarter 2023 Financial Results and Business Update
4:07pm
8-K
drk16gvw855fzvxtyzf
12 Sep 23
Humacyte Announces Positive Top Line Results from Phase 2/3 Trial of Human Acellular Vessel™ (HAV™) in Treatment of Patients with Vascular Trauma
7:09am
8-K
lefejqk7rl8updato74r
14 Aug 23
Humacyte Second Quarter 2023 Financial Results and Business Update
7:05am
8-K
97ybby0sx
26 Jul 23
Humacyte Completes Enrollment in Phase 2/3 Trial of
8:07am
424B3
uf5hjwzat2ajf42
22 Jun 23
Prospectus supplement
6:50am
EFFECT
7fc r0gqo4ok3u
22 Jun 23
Notice of effectiveness
12:15am
CORRESP
2s6y6 bo1mbv
16 Jun 23
Correspondence with SEC
12:00am